Could a common arthritis drug ease skin woes in down syndrome?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females with DS between 12 and 50 years of age who weigh at least 40 kg. * Diagnosis of at least one active immune skin condition, including but not limited to: 1. Moderate-to-severe atopic dermatitis 2. Alopecia areata affecting at least 25% of the scalp 3. Moderate-to-severe hidradenitis suppurativa 4. Moderate-to-severe psoriasis 5. Moderate-to-severe vitiligo. * Be willing to avoid pregnancy or fathering children. * Must present with a study partner or legal guardian who can complete, or assist with completing, study materials as appropriate. Exclusion Criteria * Weigh less than 40 kg. * Pregnancy or breast feeding. * No study partner or legal guardian. * Vaccination with live attenuated virus within six weeks of inclusion in the study or planned during the study. * Clinically significant chronic or active viral infection including but not limited to HIV, hepatitis, CMV, EBV, HSV. * Severe renal impairment. * History of malignant solid tumor cancer within five years prior to study entry or where there is current evidence of recurrent or metastatic disease. * Poor venous access not allowing repeated blood tests or non-compliance with venipuncture requirements. * Prior treatment with a JAK inhibitor or with an investigational agent, device, or procedure within 21 days of enrollment. * Concomitant treatment with other immunosuppressants (e.g. corticosteroids, methotrexate) or strong CP3A4 or CYP2C19 inhibitors or inducers (e.g. ketoconazole, fluconazole). * Known allergies, hypersensitivity, or intolerance to Tofacitinib. * History of thrombotic disorder. * Superficial skin infection within 2 weeks of inclusion in the study. * History of disseminated herpes zoster, disseminated herpes simplex, or recurrent localized dermatomal herpes zoster. * Intravenous antimicrobial therapy within 3 months of inclusion in the study. * Oral antimicrobials within 2 weeks of inclusion in the study. * Participants may be excluded for other unforeseen reasons at the study doctor's discretion. * Unable to provide assent in cases where informed consent is obtained from other authorized representative. * Kidney transplant within the last two years * Any history of heart attack or stroke. * Any history of lymphoma. * Past or current smokers.